|
Cadila Healthcare () is an Indian pharmaceutical company headquartered at Ahmedabad in Gujarat state of western India. The company is the fifth largest pharmaceutical company in India,〔(【引用サイトリンク】title=A Complete Overview on Cadila Healthcare, a growing and popular company in India. )〕 with INR 29.78 Bn in turnover in 2011. It is a significant manufacturer of generic drugs. == History == Cadila was founded in 1952 by Ramanbhai Patel(1952–2001), formerly a lecturer in the L.M. College of Pharmacy, and his business partner Indravadan Modi. It evolved over the next four decades into an established pharmaceutical company. In 1995 the Patel and Modi families split, with the Modi family's share being moved into a new company called Cadila Pharmaceuticals Ltd. and Cadila Healthcare became the Patel family's holding company. Cadila Healthcare had its initial public offering on the Bombay Stock Exchange in 2000 as stock code 532321. In 2015 the company acquired another Indian pharmaceutical company called German Remedies. On June 25, 2007, the company acquired Química e Farmacêutica Nikkho do Brasil Ltda (Nikkho) as part of Zydus Healthcare Brasil Ltda.〔(Company Overview of Química e Farmacêutica Nikkho do Brasil Ltda ) ''Bloomberg''〕 In 2010, Cadila Healthcare received a Wellcome Trust Award under the "R&D for Affordable Healthcare in India" initiative. In 2014, Cadila Healthcare launched the world's first ''adalimumab biosimilar'' under the brand name Exemptia at one-fifth the originator's price.〔(Zydus Cadila launches biosimilar of AbbVie's Humira in India ) ''The Economic Times'' 9 December 2014〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Cadila Healthcare」の詳細全文を読む スポンサード リンク
|